Turbine Raises €20M in Series A Financing
Summary
In conjunction with the financing, MSD GHI Fund and Mercia Asset Management have delegated members to Turbine’s new Board. The company intends to use the funds to drive its first-in-class programs targeting DNA Damage Repair. Founded by Kristof Szalay, Daniel Veres, and Szabolcs Nagy (CEO), Turbine has developed and validated the Simulated Cell, a proprietary and platform that runs billions of simulations prior to ever initiating preclinical development guiding real-life experiments with invaluable biological insights. Its technology leverages artificial intelligence (AI) to build a constantly evolving, predictive simulation of cellular signaling. Simulations have already been validated from target discovery to patient stratification and life cycle management in collaborations with multiple big pharma companies.
Funding
Review available funding amount, funding date, investors, and linked company information related to Turbine Raises €20M in Series A Financing in the interactive ISVWorld profile.